Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Senseonics Holdings, Inc. (NYSE American: SENS) announced participation in the upcoming Morgan Stanley Global Healthcare Conference in New York. On October 5, 2022, the company granted 6 non-executive employees stock options for a total of 78,000 shares at an exercise price of $1.34, contingent on continued service and vesting after one year. Senseonics aims to expand its Eversense CGM System availability and enhance the product, which continuously measures glucose levels for up to 6 months, providing an alternative to traditional fingerstick tests.
Senseonics Holdings, Inc. (NYSE American: SENS) announced its participation in the Morgan Stanley Global Healthcare Conference on September 13, 2022, at 7:20 am ET in New York, NY. The event will include one-on-one meetings, and interested parties can access a live and recorded webcast via the company's website at www.senseonics.com. Senseonics specializes in long-term, implantable continuous glucose monitoring systems, aiming to enhance the lives of those with diabetes.
Senseonics Holdings, Inc. (AMEX: SENS) announced the transition of its Chief Financial Officer, Nick Tressler, effective September 1, 2022. Rick Sullivan, the current Vice President of Finance, will succeed Tressler. The company emphasizes Sullivan's proven track record and leadership abilities to enhance operational and financial performance. Tressler will remain with Senseonics in a supporting role until the end of the year. The transition is expected to continue the company's strategic initiatives in the medical technology sector, specifically in long-term glucose monitoring systems.
Senseonics Holdings, Inc. (NYSE American: SENS) plans to present at the Inaugural Gilmartin Group Emerging Showcase virtually on August 31, 2022, at 3:00pm ET. The company specializes in developing long-term, implantable continuous glucose monitoring systems for diabetes management. Interested parties can access a live and archived webcast of the presentation on the company’s website at www.senseonics.com. The Eversense® CGM systems provide real-time glucose data through a small sensor under the skin, enhancing diabetes care.
Senseonics Holdings, Inc. (NYSE American: SENS) reported a revenue of $3.7 million for Q2 2022, up from $3.3 million in Q2 2021. The U.S. revenue increased to $1.2 million from $1.0 million year-over-year. Gross profit improved to $0.8 million, up from $0.4 million. Notably, the company recorded a net income of $104.2 million, attributed to adjustments in embedded derivatives. Senseonics also reaffirmed its full-year revenue guidance of $14.0 million to $18.0 million. Recent highlights included CE mark approval for the E3 system and improved patient access through coverage decisions.
Senseonics Holdings, Inc. (AMEX: SENS) announced that Anthem is providing coverage for its Eversense E3 Continuous Glucose Monitoring (CGM) System, adding over 45 million covered lives. This expands the total coverage for Eversense to approximately 250 million lives in the U.S. The Eversense CGM offers a six-month sensor life, accurate glucose data, and remote monitoring capabilities for diabetes management. The decision follows similar coverage expansions by other major insurers, enhancing the accessibility of this advanced monitoring technology.
Senseonics Holdings, Inc. (NYSE American: SENS) announced plans to release its Q2 2022 financial results on August 9, 2022, after market close. Management will review the performance during a conference call at 4:30 p.m. (ET), which will be available via a webcast on the company's website. Senseonics specializes in long-term implantable continuous glucose monitoring (CGM)/b) systems, including Eversense®, Eversense® XL, and Eversense® E3, providing automatic glucose data updates every five minutes to users' mobile apps.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants to 17 new non-executive employees under its 2019 Inducement Plan. Each employee received non-qualified stock options to purchase 199,000 shares at an exercise price of $1.02 per share, corresponding to the closing price on July 1, 2022. The options will vest over four years, contingent on continued employment. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management globally.
Senseonics Holdings, Inc. has received CE Mark approval for the Eversense® E3 CGM System, allowing commercialization in select European markets. The E3 system is the longest-lasting continuous glucose monitoring device, with a wear duration of up to 6 months and superior accuracy. Ascensia Diabetes Care, Senseonics’ commercial partner, will launch the product in Germany, Italy, Spain, and other EU countries starting Q3 2022. The E3 system enhances operational efficiency and supports non-adjunctive use, improving treatment decisions without confirmatory fingerstick tests.
Senseonics Holdings, Inc. (AMEX: SENS) announced its participation in the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022, at 1:30pm ET. The presentation will be accessible via a live and recorded webcast on the company's website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, including Eversense® devices, designed to aid diabetes management. The company aims to transform lives by providing innovative glucose monitoring solutions.